Zenith and Resverlogix are about to kick things up a notch in terms of events on the Q2 2016 calendar. You can always go to the events pages for Zenith and Resverlogix to see the complete list with web links to each conference, but here are my notes.

American Association for Cancer Research (AACR) meeting is April 16-20 in New Orleans. Zenith will be presenting on Monday 4/18 in a Late Breaking Poster Session. On Tuesday 4/19 and Wednesday 4/20, Zenith's Eric Campeau presents at the Epigenetics Inhibitor Discovery meeting in San Diego. Eric's 4/19 talk, as well as the 4/18 AACR poster, are titled "Preclinical Characterization of ZEN-3694, a Novel BET Bromodomain Inhibitor Entering Phase I Studies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)." The abstract for AACR won't be posted until 4/15 but here is Eric's talk description for 4/19.

"Targeting of proteins involved in the epigenetic regulation of oncogenesis has been motivated by the elucidation of their pivotal roles in various cancer programs, as well as the recent discovery of small molecules that could potently inhibit these proteins. Of these, inhibition of the bromodomain and extra-terminal (BET) proteins has shown potent inhibition of several transcriptional programs known to promote tumorigenesis, and promising evidence of clinical activities in leukemia and lymphoma have been presented. ZEN-3694 is a novel pan-BET bromodomain inhibitor displaying anti-tumor activity in various preclinical models. In vitro and in vivo characterization of ZEN-3694 will be presented, as well as evidence of activities in various models of CRPC that are resistant to current therapies. An overview of the planned phase I clinical trial in mCRPC with ZEN-3694 will also be discussed."

On Wednesday 4/20, Eric will be moderating a discussion on Next-Generation BET Bromodomain Inhibitors with the following focus topics copied from the conference website:

"Do bromodomain-1 or bromodomain-2 specific inhibitors provide advantages over pan-BET bromodomain inhibitors?

What advantages do pan-BET inhibitors provide?

What are the prospects for other bromodomain inhibitors and working out their phenotypes?

Designing combination therapies with BET bromodomain inhibitors"

Then a little break before the Epigenetics: Cancer and Beyond meeting in New York April 28th, at which both Zenith and Resverlogix are chairing and presenting.

2:45 PM "Beneficial Effects of BET Inhibition on Cardiovascular Disease" (preliminary title)

Ewelina Kulikowski, PhD, Resverlogix Corp

"New Horizons for BET Inhibition: Apabetalone for the Treatment of High-Risk Cardiovascular Disease

Ewelina Kulikowski, PhD, Resverlogix Corp., Calgary

"Epigenetic pathophysiology derived from either constitutional or environmental causes is important in many disease processes. Apabetalone, an inhibitor of the epigenetic regulators bromodomain and extraterminal (BET) proteins, is currently in a phase 3 secondary prevention outcomes trial (BETonMACE; NCT02586155) in patients with cardiovascular disease (CVD) and diabetes mellitus (DM). In phase 2b post-hoc analysis, Apabetalone treatment of patients with CVD resulted in a 55% relative risk reduction in major adverse cardiac events (MACE) following 6 months of treatment, almost exclusively accounted for by favorable effects in those with DM co-morbidity and/or those with heightened inflammation (elevated C-reactive protein). A hallmark of many diseases such as cancer, inflammation and more recently CVD, is aberrant transcription. BET proteins control recruitment of transcriptional machinery to coordinate this process. BET inhibition by apabetalone has been shown to modulate gene expression pathways that underlie CVD including reverse cholesterol transport, acute phase response, vascular inflammation, coagulation and complement. BET inhibition by apabetalone has been shown to reduce expression and secretion of components of the complement and coagulation cascades as well as mediators of the acute phase response and vascular inflammation, in vitro and in vivo. Moreover, apabetalone targets markers of inflammation, thrombosis, plaque instability and modulates innate immune pathways in CVD patients. Those effects may explain the lower incidence of MACE observed in clinical trials. Because of its multimodal action, BET inhibition is a novel target for therapeutic intervention in CVD, DM, neurodegenerative disease and a variety of orphan indications."

3:20 PM: Networking Coffee Break (my note: nice to see a Resverlogix/Zenith coffee break sandwich here).

3:50 PM "Preclinical Characterization of ZEN-3694, a Novel BET Bromodomain Inhibitor Entering Phase I Studies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)"

Eric Campeau, PhD, Zenith Epigenetics

Talk abstract is the same as the one above for the 4/19 Epigenetic Inhibitor Discovery meeting.

After this, nothing in May listed for Zenith. In June, Zenith will attend American Society for Clinical Oncology (I don't know if they are presenting) and also have the June 6-9 BioInternation Convention on their events page.

Resverlogix event page for May/June is a little busier. For the science conferences (ATVB/PVD, ERA/EDTA, EAS, ADA) it is unclear at this time whether they are presenting or just attending.

May 2-3: Bloom Burton & Co. Healthcare Investor Conference, Toronto, ON. Presenting on May 2.

May 2-4: BioNetwork East, Orlando, FL. Presenting on May 2.

May 5-7: ATVB/PVD, Nashville, FL.

May 21-24: ERA/EDTA, Vienna, Austria.

May 29-June 1: EAS 2016, Innsbruck, Austria.

June 6-9: BIO International Convention, San Francisco, CA (on both Resverlogix and Zenith schedule of events)

June 10-14: ADA Scientific Sessions, New Orleans, LA.